CytomX has raised a total of $65 million from premier life sciences investors. In 2010, CytomX completed a $30 million Series B financing led by Third Rock Ventures and including the Roche Venture Fund. In 2012, Canaan Partners led an expansion of the Series B to $41 million. In January 2015, CytomX announced a $20 million Series C financing led by Pfizer Venture Investments that included all existing investors.

Third Rock Ventures
Third Rock Ventures Third Rock Ventures is a venture capital firm founded in 2007 with the mission to launch transformative life sciences companies. With more than $1.3 billion and three funds under management, the firm is focused on working with passionate entrepreneurs to build exceptional companies working in areas of disruptive science that will make a difference in the lives of patients.

Roche Venture Fund
Roche The Roche Venture fund invests in early-stage biotech diagnostics companies to develop commercially successful innovative life science companies. Based in Basel with an office in South San Francisco, the Roche Venture Fund invests globally with a portfolio of about 30 companies in 10 countries.

Canaan Partners
Canaan Partners Canaan Partners invests in entrepreneurs and works alongside them to turn visionary ideas into valuable companies. Since 1987, the firm has catalyzed the growth of disruptive technology startups and healthcare companies revolutionizing the practice of medicine. With $3.5 billion under management and more than 85 acquisitions and 53 IPOs to date, Canaan maintains a presence in the global innovation hubs of New York, Silicon Valley, India and Israel.

Pfizer Venture Investments
Pfizer Venture Investments Pfizer Venture Investments, the venture capital arm of Pfizer Inc., was founded in 2004 and invests for return in areas of current or future strategic interest to Pfizer. As part of the Worldwide Business Development division, PVI seeks to remain at the forefront of life science advances, looking to identify and invest in emerging companies that are developing compounds and technologies that have the potential to enhance Pfizer's pipeline and shape the future of our industry.